On September 26, 2025, Moleculin Biotech, Inc. announced that the Canadian Intellectual Property Office (CIPO) issued a notice of allowance for Patent Application No. 3,142,510, titled 'PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE.' The notice confirms that the application has met CIPO’s requirements and is now in the final stage before formal issuance.
The patent covers methods for producing a preliposomal Annamycin lyophilizate with improved stability and high purity, providing the company with a robust intellectual‑property shield for its lead drug candidate. The base term of the patent extends to June 2040, offering long‑term exclusivity in Canada and strengthening Moleculin’s global IP portfolio.
Annamycin, the company’s next‑generation anthracycline, is being developed for relapsed or refractory acute myeloid leukemia and soft‑tissue sarcoma lung metastases. The Canadian allowance complements existing U.S. and European patents and supports Moleculin’s strategy to secure market protection for Annamycin as it advances toward regulatory approval.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.